Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of BPX-201 Vaccine Plus AP1903 in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

NCT01823978 is registered in ClinicalTrials.gov with Bellicum Pharmaceuticals as lead sponsor.

NCT NCT01823978
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01823978 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of BPX-201 Vaccine Plus AP1903 in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Lead sponsor
Bellicum Pharmaceuticals
Phase
Phase 1
Overall status
Completed
Start date
April 30, 2013
Completion date
September 30, 2017
Enrollment
19 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

castrate resistent prostate cancer